Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 78.84
-6.68 (-7.81%)
Jul 31, 2025, 5:38 PM CET
Everi Holdings Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025, a decrease of -5.67%. This brings the company's revenue in the last twelve months to 45.74B, down -2.85% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B
Revenue Growth
-2.85%
P/S Ratio
2.28
Revenue / Employee
551.87K
Employees
82,878
Market Cap
104.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sartorius Stedim Biotech | 2.90B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.57B |
| ABIVAX Société Anonyme | 10.59M |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
Sanofi News
- 3 hours ago - Trump pressures 17 pharma CEOs to cut US drug prices - Reuters
- 3 hours ago - Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days - CNBC
- 5 hours ago - Press release: Online availability of Sanofi's half-year financial report for 2025 - GlobeNewsWire
- 7 hours ago - Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales - Benzinga
- 15 hours ago - Sanofi revises annual sales growth expectations on strong Dupixent demand - Reuters
- 16 hours ago - Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range - GlobeNewsWire
- 1 day ago - Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma - GlobeNewsWire
- 2 days ago - U.S. and European Union trade deal could cost the pharma industry up to $19 billion - Fast Company